Bosentas 62.5 mg (Bosentan)
Bosentas 62.5 mg contains bosentan, an oral dual endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and slow disease progression. Bosentan requires specialist prescription and careful monitoring due to important liver and reproductive safety considerations. :contentReference[oaicite:0]{index=0}
Product introduction
Bosentan blocks endothelin-1 signalling (via ETA and ETB receptors), reducing vasoconstriction and vascular remodelling in the pulmonary circulation. The 62.5 mg tablet is the usual starting strength used in titration regimens before increasing to maintenance dosing under clinician supervision. :contentReference[oaicite:1]{index=1}
Uses of Bosentas 62.5 mg (Bosentan)
Clinical indications (specialist-directed):
- Treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity and symptoms
- Part of combination therapy strategies for PAH (with PDE-5 inhibitors, prostacyclins or others as judged by a specialist)
Note: Initiation and follow-up should be performed by clinicians experienced in PAH management. Treatment algorithms vary by region and patient characteristics. :contentReference[oaicite:2]{index=2}
Benefits of Bosentas 62.5 mg
- Improves exercise tolerance: demonstrated benefits in clinical trials for walking distance and symptoms.
- Targets vascular pathology: acts on endothelin pathways implicated in PAH progression.
- Oral administration: convenient for long-term outpatient therapy when monitored appropriately.
Recommended dosing
The commonly recommended adult regimen is to start 62.5 mg twice daily for 4 weeks then increase to a maintenance dose of 125 mg twice daily, provided liver tests and clinical status permit. Lower weight or certain co-medication situations may require adjusted regimens—follow your prescriber’s instructions. Re-introduction after interruption generally restarts at the initial titration dose. :contentReference[oaicite:3]{index=3}
Side effects of Bosentas 62.5 mg
Key adverse effects and safety concerns:
Common side effects
- Headache
- Flushing
- Nasopharyngitis, upper respiratory symptoms
- Peripheral oedema
Serious/important risks: hepatotoxicity (elevated aminotransferases, liver injury) and severe teratogenicity. Monthly liver enzyme monitoring and strict pregnancy prevention are mandatory for people of reproductive potential. Immediate evaluation is required for signs of liver injury (jaundice, dark urine, severe abdominal pain) or unexplained illness. :contentReference[oaicite:4]{index=4}
How to use Bosentas 62.5 mg
- Take exactly as prescribed—usually twice daily (morning and evening), with or without food.
- Adherence to monthly blood tests (liver enzymes) is essential; do not continue therapy without monitoring.
- Women of childbearing potential must have a negative pregnancy test before starting, use reliable contraception and repeat testing monthly while on treatment and for one month after stopping. Bosentan is contraindicated in pregnancy. :contentReference[oaicite:5]{index=5}
- Do not share medication; any interruptions or planned pregnancies should be discussed with the treating specialist immediately.
How Bosentas works
Bosentan antagonises endothelin-1 receptors (ETA and ETB), reducing vasoconstriction and vascular cell growth in pulmonary arteries — mechanisms central to PAH pathophysiology. This leads to reduced pulmonary vascular resistance and symptomatic improvement in many patients. :contentReference[oaicite:6]{index=6}
Safety advice
| Pregnancy | Contraindicated — bosentan causes major birth defects. Exclude pregnancy before starting and enforce effective contraception during treatment and for one month after stopping. Join any local pregnancy-prevention / REMS program as required. :contentReference[oaicite:7]{index=7} |
| Liver monitoring | Check baseline ALT/AST and bilirubin and then monthly while on treatment. Interrupt or stop therapy if AST/ALT ≥3× ULN with symptoms or ≥5× ULN without symptoms per product guidance. :contentReference[oaicite:8]{index=8} |
| Drug interactions | Bosentan has clinically important interactions (CYP and transporter effects). It is contraindicated with cyclosporine A and glyburide in many labels and dose adjustments/avoidance are needed with strong CYP3A4/P-gp inhibitors or inducers (e.g., ritonavir, ketoconazole, rifampin) — discuss all medicines, herbal products and supplements with your clinician/pharmacist. :contentReference[oaicite:9]{index=9} |
| Hepatic disease | Avoid or use caution in pre-existing moderate–severe hepatic impairment; bosentan may be inappropriate where monitoring cannot be ensured. :contentReference[oaicite:10]{index=10} |
| Concomitant PAH therapies | Often used in combination with PDE-5 inhibitors or prostacyclin analogues — combinations should be managed by PAH specialists due to interaction and additive effect considerations. :contentReference[oaicite:11]{index=11} |
What if you forget a dose?
- Take the missed dose as soon as you remember on the same day, maintaining the twice-daily schedule.
- If it is nearly time for the next dose, skip the missed dose and resume your usual schedule.
- Do not double doses to make up for missed doses. For repeated missed doses, contact your prescribing specialist. :contentReference[oaicite:12]{index=12}
All substitutes
Other endothelin receptor antagonists and PAH options (specialist selection):
- Ambrisentan (selective ERA)
- Macitentan (ERA with different profile)
- PDE-5 inhibitors (sildenafil, tadalafil), prostacyclin analogues, soluble guanylate cyclase stimulators — choice depends on patient risk profile and specialist judgement
Quick tips
- Register with any local REMS/pregnancy-prevention programme if required.
- Bring an up-to-date medicines list to all appointments and tell other providers you are taking bosentan.
- Attend monthly blood tests and report symptoms of liver injury or pregnancy immediately.
- Carry an alert card noting bosentan therapy and reproductive/monitoring requirements.
Fact Box
| Generic name | Bosentan |
| Brand | Bosentas 62.5 mg |
| Drug class | Endothelin receptor antagonist (dual ETA/ETB) |
| Form | Oral tablet (62.5 mg) |
| Typical dosing | Start 62.5 mg twice daily for 4 weeks then increase to 125 mg twice daily (monitoring required). Adjust if interacting drugs present. :contentReference[oaicite:13]{index=13} |
| Prescription | Specialist prescription; monitoring required |
Patient concerns
Will Bosentas cure PAH? No. Bosentan is used to improve symptoms, exercise capacity and delay progression in PAH as part of a comprehensive specialist treatment plan—outcomes vary by disease severity and combination therapy.
Why are liver tests needed every month? Bosentan can raise liver enzymes and cause serious liver injury that may be asymptomatic early on—monthly tests detect problems before severe damage occurs. :contentReference[oaicite:14]{index=14}
User feedback
Specialist-treated patients report improved walking distance and symptom control when bosentan is used appropriately with monitoring. Common patient concerns relate to liver monitoring and strict pregnancy prevention requirements.
FAQs
Can I become pregnant while taking Bosentas?
No — bosentan is contraindicated in pregnancy. Females of reproductive potential must have a negative pregnancy test before starting, use effective contraception (often two methods), and have monthly testing while on treatment and for one month after stopping. :contentReference[oaicite:15]{index=15}
Are there drugs I must avoid while on Bosentas?
Certain medicines (notably cyclosporine A and glyburide) are contraindicated with bosentan; many strong CYP3A4/P-gp inhibitors or inducers require caution or dose changes — disclose all medicines and supplements to your specialist or pharmacist. :contentReference[oaicite:16]{index=16}
How should I store Bosentas?
Store at room temperature away from moisture and heat. Keep out of reach of children and do not use past the expiry date.
Related products
- Ambrisentan, Macitentan (other ERAs)
- Sildenafil, Tadalafil (PDE-5 inhibitors)
- Prostacyclin analogues and receptor agonists (specialist use)
Want to share the information?
Share this article to help patients and caregivers understand bosentan therapy and the importance of monitoring and pregnancy prevention.
Disclaimer:
This article is educational only and does not replace specialist medical advice. Bosentas (bosentan) must be prescribed and monitored by clinicians experienced in PAH management. Follow local product labeling and programs (REMS/pregnancy prevention) where applicable. :contentReference[oaicite:17]{index=17}
References & authoritative sources
- Tracleer (bosentan) prescribing information — FDA. :contentReference[oaicite:18]{index=18}
- EMA Product Information (Tracleer). :contentReference[oaicite:19]{index=19}
- MedlinePlus / clinical monographs on bosentan safety and monitoring. :contentReference[oaicite:20]{index=20}
- Primary PAH literature & pharmacology reviews. :contentReference[oaicite:21]{index=21}
Marketer details
genericurerx — support@genericurerx.com — www.genericurerx.com
In case of any issues, contact us
For ordering or prescription verification use live chat or our contact page. For medical concerns contact your PAH specialist or treating clinician immediately.
Lab tests offered by us
- Baseline and monthly liver function tests (ALT, AST, bilirubin)
- Pregnancy testing for females of reproductive potential
- Routine PAH follow-up (6MWD, BNP, echocardiography) as clinically indicated
Additional offers
Prescription coordination, PAH counselling and specialist referral support available on request. Use code GLOBAL10 where eligible for first-order discounts.
Reviews
There are no reviews yet.